Background
==========

Obesity refers to excessive accumulation and abnormal distribution of fat in the body, usually accompanied by weight gain. The World Health Organization (WHO) defines obesity as an abnormal or excessive accumulation of fat that can lead to health damage \[[@b1-medscimonit-26-e924882]\]. According to the survey of nutrition and health status of Chinese residents of 2002, the overweight rate and obesity rate of Chinese residents were 17.6% and 5.6% respectively. The sum of the 2 was 23.2%, which was close to a quarter of the total population. Obesity has become an important disease affecting the health of Chinese residents \[[@b2-medscimonit-26-e924882]\]. Obesity is a major risk factor for many diseases, such as hypertension, diabetes, dyslipidemia, coronary heart disease, myocardial infarction, stroke, and several types of cancer, including breast cancer. It has been recognized as the fifth most important major risk factor affecting health \[[@b3-medscimonit-26-e924882]\]. Some studies had found that ceruloplasmin, fibrinogen, and apolipoprotein A-IV were overexpressed in plasma of obese people; therefore, they might be potential protein markers of obesity \[[@b4-medscimonit-26-e924882],[@b5-medscimonit-26-e924882]\]. In contrast, apolipoprotein A-1 and apolipoprotein E were lower in plasma of obese and overweight people compared with the normal population \[[@b5-medscimonit-26-e924882]\]. Some studies demonstrated that level of the thermogenic enzymes was higher while the level of lipid synthase was lower in obesity-resistant mice \[[@b6-medscimonit-26-e924882]\]. Cytochrome b-cl complex subunit 1, enol3, monoglyceride lipase, and glucose-6 phosphate dehydrogenase 1 participate in energy metabolism in mice, such as glycolysis and visceral adipose tissue formation; thus, they may also be involved in the molecular mechanism and metabolic pathway of obesity \[[@b7-medscimonit-26-e924882]\].

Proteomics is a recently-developed method to study the molecular mechanism of diseases. iTRAQ technology is a proteomic technology introduced by Applied Biosystems, Inc. in 2004, in which 4 or 8 samples under the same experimental conditions can be quantitatively studied simultaneously by using isotope labeling technology. iTRAQ reagents comprised heterotopic labeling molecules with molecular weight of 145 Da. The labeling molecules are made up of reporting group with molecular weights of 114, 115, 116, 11, 118, 119, and 121Da, equilibrium group, and a same polypeptide reaction group. The technique has very good accuracy and high repeatability. It can be used to analyze several different samples simultaneously. When combined with the chromatographic separation system, it can be used to detect large-scale protein alterations by detecting microgram-level amounts of protein, thus providing large-scale quantitative information on proteins. Another advantage is its wide application, as it can assess any type of protein. Compared with gel electrophoresis, this technology can be used to identify large molecular weight proteins, extremely acidic proteins, and extremely basic proteins, as well as low solubility and even insoluble membrane proteins; thus, the range of proteins identified is greatly expanded \[[@b8-medscimonit-26-e924882]\].

In the present study, we used iTRAQ technique to identify the differentially expressed proteins of obese patients compared with normal participants, to explore the potential molecular mechanism of obesity.

Material and Methods
====================

Participants and enrollment
---------------------------

Adults with BMI \>28.0 kg/m^2^ were categorized as obese, as specified in the Guidelines for the Prevention and Control of Overweight and Obesity in Adults of China promulgated and implemented by the Ministry of Health in 2002 \[[@b9-medscimonit-26-e924882]\]. We included 10 obese subjects and 10 normal subjects. Inclusion criteria of the obesity group were: male; age 18--44 years old; BMI ≥28.0 kg/m^2^; no organic diseases; and normal blood pressure and serum glucose ([Table 1](#t1-medscimonit-26-e924882){ref-type="table"}). Matched controls were enrolled in a ratio of 1: 1. The inclusion criteria of the control group were: male; age 18--44 years old; 18.5 kg/m^2^ ≤BMI \<24.0 kg/m^2^; no organic diseases; and normal blood pressure, serum glucose, serum lipid, and hemoglobin levels. All subjects signed the informed consent. The research was approved by the Ethics Committee of Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University.

Reagents and instrument
-----------------------

The system in the MARS.14 chromatographic column was obtained from Aglient Co.; the iTRAQ kit, QSTAR XL mass spectrometer, and Protein Pilot4.2 software were obtained from Applied Biosystems (USA); the liquid chromatograph (20AD) was obtained from Shimadzu Co. (Japan); Strong Cation Exchange Chromatography (2.1×100 mm, 5 um, 300 A) was obtained for the Nest Group Inc. System (USA); and the ZORBAX 300SB-C18 column (5 um, 300A, 0.1×150 mm) was obtained from Microm Co. (USA).

Sample collection and preparation
---------------------------------

We collected 4 mL fasting venous blood and placed it in a tube. After being frozen on ice for 30 min, the sample was centrifuged under 2000 r/min for 10 min at 4°C. Supernatant was collected in 1.5-mL EP tubes before being stored at −80°C.

Removal of high-abundance proteins
----------------------------------

High-abundance proteins were removed using the multiple affinity removal system human 14 chromatograph. The fractions collected were concentrated by freeze-drying.

ITRAQ labeling
--------------

One hundred ug samples of each group were added with reducing reagent, at 60°C for 1 h. Then, cysteine blocking reagent was added and placed at room temperature for 10 min. Trypsin was added and enzymatic hydrolysis was allowed at 37°C overnight. Then, samples were centrifuged to deposit, and iTRAQ labeling reagent was added to each sample. Reaction was allowed for 1 h at room temperature and 3 times the volume of super-pure water was added to dilute the labeling reagent. The sample of the obese group was labeled with iTRAQ 118 and samples of the normal group were labeled with iTRAQ 117. The labeled samples were mixed in a low-adsorption tube and underwent vacuum centrifugal evaporation drying, followed by storage at −80°C.

Strong cation exchange chromatography (SCX) and mass spectrometric analysis
---------------------------------------------------------------------------

We added 200 uL SCX buffer A to the labeled sample mixture, stratified by SCX. After stratification, samples were analyzed by nano liquid chromatography electron spray ionization mass spectrometry (nano-LC-ESI-MS/MS) system. The scanning range of paper and pen was 400--1800 m/z.

Mass spectrometric data analysis
--------------------------------

The data obtained with mass spectrometric analysis were retrieved by Protein Pilot 4.2 software, using the Paragon method. Protein identification confidence level was set as 95%, Prot Score \>1.3, and a peptide above 95% matched peptides in the library. At the same time, a protein reverse library search was made. The FDR \<5%, Ratio \>1.2 or Ratio \<0.8 was regarded as differential expression.

Gene Ontology (GO) functional analysis
--------------------------------------

All differentially expressed proteins identified by the approaches above were assigned their gene symbol via the PANTHER database (Protein Analysis through Evolutionary Relationships, *<http://www.pantherdb.org/>*). Protein classification was performed based on their functional annotations using GO for biological process, molecular function, and cellular component. When more than 1 assignment was available, all of the functional annotations were considered in the results.

Data analysis and statistics
----------------------------

The data are presented as mean±SD and were assessed by *t* test. Differences with p values \<0.05 were considered to be statistically significant.

Results
=======

Age, BMI, blood pressure, and glucose of subjects
-------------------------------------------------

The BMI of obese group was significantly higher than that of the control group ([Table 1](#t1-medscimonit-26-e924882){ref-type="table"}). However, their age, systolic blood pressure, diastolic blood pressure, and glucose were normal and had no significant differences (p\>0.05) ([Table 1](#t1-medscimonit-26-e924882){ref-type="table"}).

Basic data of identified proteins
---------------------------------

A total of 9622 differential peptides were identified, corresponding to 733 proteins; 118 proteins showed significant differential expression, with 15 upregulated and 103 downregulated ([Table 2](#t2-medscimonit-26-e924882){ref-type="table"}). The upregulated proteins included IGL@ protein, C-reactive protein, Putative uncharacterized protein, and Suprabasin ([Table 3](#t3-medscimonit-26-e924882){ref-type="table"}). The downregulated proteins included Thioredoxin reductase 2, Costars family protein ABRACL, Kelch domain containing 5, and POTE ankyrin domain family member J ([Table 4](#t4-medscimonit-26-e924882){ref-type="table"}). The downregulated Apo-lipoproteins included apolipoprotein B variant, ApoB, and ApoM. The downregulated energy metabolism-related proteins included phosphoglycerate kinase 1, N-fatty-acyl-amino acid synthase, and glucose-6-phosphate isomerase.

Enrichment analysis of differentially expressed proteins
--------------------------------------------------------

The results of Go functional annotation analysis indicated the percentage of differential expression of proteins involved in every biological procedure, molecular function, and cellular component ([Figure 1](#f1-medscimonit-26-e924882){ref-type="fig"}). The items with high percentage of differential proteins were involved in included cellular processes, signaling process, binding, cell part, and organelles ([Figure 1](#f1-medscimonit-26-e924882){ref-type="fig"}). Furthermore, the top 30 enriched GO terms indicated the significantly enriched GO terms involved by the differentially expression of proteins ([Figure 2](#f2-medscimonit-26-e924882){ref-type="fig"}). The significantly enriched GO terms included actin cytoskeleton, contractile fiber, myofibril, and platelet aggregation ([Figure 2](#f2-medscimonit-26-e924882){ref-type="fig"}).

KEGG enrichment pathway analysis of differentially expressed proteins
---------------------------------------------------------------------

The top 30 enriched pathways involved with differential proteins were demonstrated. These pathways included salmonella infection, tight junction, shigellosis, and regulation of actin cytoskeleton ([Figure 3](#f3-medscimonit-26-e924882){ref-type="fig"}).

Discussion
==========

The incidence of obesity in China is increasing rapidly. At present, more than one-half of males are overweight. The increase of abdominal obesity in men is fairly obvious, even in young males. It is necessary to investigate obesity to prevent and control the development and progression of obesity. In this study, we used iTRAQ technology to analyze the serum proteomics among obese male patients, and identified several obesity-related proteins, thereby providing a basis for further research on obesity.

According to the results of this study, the level of C-reactive protein was significantly higher in serum of obese patients, which was consistent with previous studies \[[@b10-medscimonit-26-e924882],[@b11-medscimonit-26-e924882]\]. We found that upregulation of C-reactive protein promoted chronic inflammatory status. C-reactive protein is a pro-inflammation factor and can strongly predict the risk of cardiovascular events, since it can mediate cardiovascular impairment. Some studies have demonstrated that C-reactive protein in adipose cells can inhibit expression and secretion of adiponectin \[[@b10-medscimonit-26-e924882],[@b11-medscimonit-26-e924882]\]. Adiponectin is a specific protein generated by adipose cells and is associated with glucose utilization, fatty acid oxidation, and energy consumption, thus playing an important role in obesity \[[@b12-medscimonit-26-e924882]\]. In addition, adiponectin is importantly involved in formation of arteriosclerosis plaque. It can inhibit inflammation reaction through various mechanisms, thereby preventing arteriosclerosis formation. However, more investigations are needed to explore the reverse association between C-reactive protein and adiponectin and its impact on obesity.

We found that the levels of apolipoprotein B variant, ApoB, and ApoM were significantly lower in obese patients. Relevant studies have demonstrated that ApoA1, Apo A-IV, and ApoB levels were downregulated and ApoC-III was upregulated in serum of obese patients. The ratio of ApoB/ApoA1 is tightly associated with obesity, which is consistent with that of previous studies \[[@b13-medscimonit-26-e924882]--[@b16-medscimonit-26-e924882]\]. Therefore, ApoB may be a potential marker of obesity. ApoM is a recently-discovered apolipoprotein that is a member of the lipoprotein superfamily. It mainly exists in high-density lipoprotein particles. ApoM is involved in pre-beta-HDL synthesis, promotes vascular protection function of HDL, and promotes insulin release \[[@b17-medscimonit-26-e924882]\]. It is regarded as being potentially protective against atherosclerosis, coronary disease, and diabetes \[[@b18-medscimonit-26-e924882],[@b19-medscimonit-26-e924882]\]. Similar to C-reactive protein, recent studies have found that ApoM expression was significantly regulated in some inflammation-related diseases such as hepatitis, sepsis, pneumonia, and arthritis \[[@b20-medscimonit-26-e924882]\]. Thus, apart from relying on the lipid transportation function of ApoM, the association between ApoM and obesity might be more complicated, and further investigations are needed to elucidate the mechanism involved.

Moreover, levels of phosphoglycerate kinase 1, N-fatty-acyl-amino acid synthase and glucose-6-phosphate isomerase, which are closely associated with energy metabolism, were significantly lower in obese patients. However, the levels of adiponectin and leptin were not assessed, partly due to the upregulation of C-reactive protein. Therefore, studies with larger sample sizes are needed in the future.

Conclusions
===========

The development of obesity may involve a series of complex elements and mutual effects. Using the high-volume iTRAQ technique, we identified several proteins which were obviously regulated in serum of obese subjects. These proteins may provide novel directions and targets for future pathological studies of obesity.
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###### 

Basic information of 20 participants (SBP -- systolic blood pressure; DBP -- diastolic blood pressure; Mean±SD).

  Participants   Age (years old)   BMI (kg/m^2^)   SBP (mm Hg)   DBP (mmHg)   Glucose (mmol/L)
  -------------- ----------------- --------------- ------------- ------------ ------------------
  Obese          31.9±9.2          31.0±2.2        116.0±22.0    77.0±15.0    5.5±0.2
  Control        30.2±10.5         21.5±1.5        115.0±24.0    76.0±17.0    5.2±0.1
  P-value        NS                \<0.0001        NS            NS           NS

NS -- not significant.

###### 

General information of identified proteins.

  Category                                                  Number
  --------------------------------------------------------- --------
  Differential peptides                                     9622
  Differential expressed proteins                           733
  Up-regulated proteins with significance                   15
  Down-regulated proteins with significance                 103
  Total differential expressed proteins with significance   118

###### 

List of all 15 up-regulated proteins.

  Accession    Gene name        Description                                                         E/C      P-value
  ------------ ---------------- ------------------------------------------------------------------- -------- ---------
  Q6GMX3       IGL@             IGL@ protein                                                        1.5083   0.003
  P02741       CRP              C-reactive protein                                                  1.4907   0.019
  Q6N091       DKFZp686C02220   Putative uncharacterized protein                                    1.4597   0.003
  Q6MZQ6       DKFZp686G11190   Putative uncharacterized protein                                    1.4309   0.011
  Q6UWP8       SBSN             Suprabasin                                                          1.4214   0.033
  P18827       SDC1             Syndecan-1                                                          1.3535   0.020
  A0A075B7D0   IGHV1OR15-1      Protein IGHV1OR15-1                                                 1.3198   0.031
  Q96JD0                        Amyloid lambda 6 light chain variable region SAR                    1.3145   0.004
  D5H3V7       HLA-A            MHC class I antigen                                                 1.3037   0.030
  B2RP22       AKAP6            A kinase (PRKA) anchor protein 6                                    1.2919   0.026
  A0A0S2Z4L3   PROS1            Protein S isoform 2                                                 1.2812   0.0003
  Q76LX8       ADAMTS13         A disintegrin and metalloproteinase with thrombospondin motifs 13   1.2439   0.019
  B4E1B3                        cDNA FLJ53950, highly similar to Angiotensinogen                    1.2352   0.035
  Q92889       ERCC4            DNA repair endonuclease XPF                                         1.2254   0.033
  P05155       SERPING1         Plasma protease C1 inhibitor                                        1.2104   0.032

###### 

Top 15 down-regulated proteins, Apo-lipoproteins and energy metabolism related proteins.

  Accession    Gene name   Description                                                              E/C       P-value
  ------------ ----------- ------------------------------------------------------------------------ --------- ---------
  Q9NNW7       TXNRD2      Thioredoxin reductase 2, mitochondrial                                   0.3468    0.029
  Q9P1F3       ABRACL      Costars family protein ABRACL                                            0.4185    0.035
  B2RNT7       KLHDC5      Kelch domain containing 5                                                0.4256    0.004
  P0CG39       POTEJ       POTE ankyrin domain family member J                                      0.4603    0.013
  Q15555       MAPRE2      Microtubule-associated protein RP/EB family member 2                     0.4638    0.019
  Q14019       COTL1       Coactosin-like protein                                                   0.4792    0.031
  P63104       YWHAZ       14-3-3 protein zeta/delta                                                0.4929    0.022
  A0A024R1K7   YWHAH       Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein   0.4943    0.021
  A0A0K0K1I0   HEL-S-265   Epididymis secretory protein Li 265                                      0.5029    0.020
  P23528       CFL1        Cofilin-1                                                                0.5111    0.029
  P01019       AGT         Angiotensinogen                                                          0.5150    0.011
  B4DW52                   cDNA FLJ55253, highly similar to Actin, cytoplasmic 1                    0.5315    0.040
  Q9HBI1       PARVB       Beta-parvin                                                              0.5428    0.015
  V9HWH1       HEL57       Epididymis luminal protein 57                                            0.5474    0.012
  P67936       TPM4        Tropomyosin alpha-4 chain                                                0.5494    0.030
  Q7Z7Q0       APOB        APOB protein                                                             0.62485   0.005
  Q59HB3       APOB        Apolipoprotein B variant                                                 0.6868    0.0254
  O95445       APOM        Apolipoprotein M                                                         0.827     0.0015
  A0A0A0MTS2   GPI         Glucose-6-phosphate isomerase                                            0.831     0.048
  Q6GTS8       PM20D1      N-fatty-acyl-amino acid synthase                                         0.7058    0.002
  P00558       PGK1        Phosphoglycerate kinase 1                                                0.687     0.0276
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